Clinical Trial

Study of NM8074 in Adult C3 Glomerulopathy Patients

Name: Study of NM8074 in Adult C3 Glomerulopathy Patients — clinical trial record (NCT05647811)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2022-12-03; most recent amendment 2026-04-07.

Trial Details

NCT Number	NCT05647811
Lead Sponsor	NovelMed Therapeutics
Conditions	C3 Glomerulopathy
Enrollment	18 participants
Start Date	2027-05
Primary Completion	2029-08 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-13